Alnylam Pharmace. buy daimler1
Summary
This prediction ended on 02.04.23 with a price of €186.60. With a performance of 2.35%, the BUY prediction by daimler1 for Alnylam Pharmace. closed with a slight gain. daimler1 has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -1.097% | -1.097% | 21.654% |
iShares Core DAX® | 1.280% | 1.027% | 11.234% |
iShares Nasdaq 100 | -2.457% | -4.650% | 23.181% |
iShares Nikkei 225® | -2.006% | -2.091% | 6.745% |
iShares S&P 500 | -0.662% | -1.246% | 22.521% |
Comments by daimler1 for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.